Russia's new coronavirus vaccine development takes one and a half years
Innovation Connection · Russia
Dmitry Morozov, general manager of Russia's Biocad Biotechnology Corporation, said that it takes at least a year and a half to develop a new coronavirus vaccine.
Dmitry Morozov said: "Industrial production is usually carried out at the same time as clinical trials, and some stages cannot be skipped. For example, if we test the protective effect of the vaccine on mice, we need to wait at least 30 days."
Dmitry Morozov said that Biocad expects to launch at least two coronavirus vaccines on the market. He said: "Biocad cooperates with Russia's National Vector Center for Virology and Biotechnology and the Russian Institute of Experimental Medicine. The vector vector's vaccines are being tested in animals. We believe that their research work is the most promising."
In response to the cost of developing coronavirus vaccines by Biocad, Morozov said: "I think the initial stage is between 10 million and 15 million US dollars. This number may increase based on the amount of clinical trials."
He believes that the first batch of vaccines against the new corona pneumonia virus can be the same as high-quality vaccines against influenza or tick-borne encephalitis, worth 1,500 rubles (about 143 yuan). His preliminary assessment stated: "With the increase in production, we will reach the ordinary price level of high-quality influenza vaccines."